Literature DB >> 23685495

Pre-operative sub-conjunctival mitomycin C 24 hours before excision of recurrent pterygium.

V P Gupta, Pragati Gupta.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23685495      PMCID: PMC3714962          DOI: 10.4103/0301-4738.112169

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


× No keyword cloud information.
Dear Editor, We read the article by Zaky and Khalifa[1] with keen interest. We wish to express following comments: Pre-operative sub-conjunctival (SC) mitomycin C (MMC) before excision of pterygium is a recently reported adjunctive therapy with very low recurrence rates.[1234] We appreciate the authors[1] for this fascinating modification of SCMMC 24 hours before excision of recurrent pterygium. Despite the reduction in waiting period from 1 month to 24 hours, it still remains a two-stage operation.[14] Authors mention that in the mitomycin injection group, intra-operative eye irrigation with 200 mL of balanced salt solution was done following pterygium excision to wash out residual SCMMC.[1] We believe that after 24 hours of SCMMC injection, MMC would be distributed in various extra- and intraocular tissues including sclera, ciliary body and aqueous humor, resulting in rapid decrease in MMC concentration from the injection site, and there may be a very remote possibility of presence of washable MMC after excision of pterygium. Ghoneim et al. did not irrigate the conjunctival sac after excision of pterygium 24 hours after SCMMC.[4] Authors[1] mentioned in the discussion that several vision-threatening complications such as glaucoma, corneal edema, corneal perforation, scleral melting, and cataract formation have been reported from intra-operative MMC application in pterygium surgery. In fact, all these complications occurred following prolonged post-operative instillation of 0.04% MMC eye drops rather than intra-operative application.[5] Similarly, they[1] mentioned that Donnenfeld et al. reported a case series of SCMMC injection 1 month before surgery in recurrent pterygium. However, in Donnenfeld et al.'s[3] study, only 16 of the 36 eyes had recurrent pterygia, and remaining had primary pterygia. The authors[1] failed to cite Khakshoor et al.'s work who reported no recurrence after pterygium excision 1 month after sub-pterygial MMC; however, persistent whitening of sclera and hypovascularity at the site of excision occurred in 5.5% patients.[3] According to authors, pterygium excision 24 hours after SCMMC injection avoids long unnecessary exposure with subsequent penetration of MMC.[1] However, 24 hour exposure to MMC does not appear to be a short exposure time. It has been reported that 64% of the MMC was delivered to the sclera within the first minute of MMC application, and intra-operative MMC application for 5 minutes resulted in prolonged inhibition of treated fibroblasts for at least 30 days in rabbits. One study concluded that extra- and intraocular concentrations of MMC were highest after SC injection. Discussion did not include the exact mechanism of prevention of recurrence by their modification.[1] Histopathology of excised pterygia 24 hours after injection could have demonstrated the effect of MMC on fibrovascular tissues in pterygial stroma. Donnenfeld et al. performed excision of pterygia 1 month after MMC injection when pterygia became less vascular and less inflamed.[2] The histopathological and transmission electron microscopy of excised specimens of pterygia have demonstrated the inhibitory effect of MMC on fibrovascular activity in the pterygial stroma and verified the efficacy of SCMMC injection 1 month before excision of pterygia in decreasing the risk of pterygium recurrence.[26]
  6 in total

1.  Preoperative subpterygeal injection vs intraoperative mitomycin C for pterygium removal: comparison of results and complications.

Authors:  Hamid Khakshoor; Mohammad Etezad Razavi; Ramin Daneshvar; Mohammad Taghi Shakeri; Majid Farrokh Ghate; Haleh Ghooshkhanehi
Journal:  Am J Ophthalmol       Date:  2010-06-08       Impact factor: 5.258

2.  Subconjunctival mitomycin C as adjunctive therapy before pterygium excision.

Authors:  Eric D Donnenfeld; Henry D Perry; Susan Fromer; Sima Doshi; Renée Solomon; Seth Biser
Journal:  Ophthalmology       Date:  2003-05       Impact factor: 12.079

3.  Serious complications of topical mitomycin-C after pterygium surgery.

Authors:  R S Rubinfeld; R R Pfister; R M Stein; C S Foster; N F Martin; S Stoleru; A R Talley; M G Speaker
Journal:  Ophthalmology       Date:  1992-11       Impact factor: 12.079

4.  Subconjunctival mitomycin C before pterygium excision: an ultrastructural study.

Authors:  Yi-Sheng Chang; Wen-Chung Chen; Sung-Huei Tseng; Chun-I Sze; Chao-Liang Wu
Journal:  Cornea       Date:  2008-05       Impact factor: 2.651

5.  Efficacy of preoperative injection versus intraoperative application of mitomycin in recurrent pterygium surgery.

Authors:  Khaled S Zaky; Yasser M Khalifa
Journal:  Indian J Ophthalmol       Date:  2012-07       Impact factor: 1.848

6.  Preoperative subconjunctival injection of mitomycin C versus intraoperative topical application as an adjunctive treatment for surgical removal of primary pterygium.

Authors:  Ehab M Ghoneim; Ahmed A Abd-El Ghny; Amro A Gab-Allah; Mohamed Z Kamal
Journal:  Middle East Afr J Ophthalmol       Date:  2011-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.